Focused On-demand Library for Eukaryotic translation elongation factor 1 epsilon-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O43324

UPID:

MCA3_HUMAN

Alternative names:

Aminoacyl tRNA synthetase complex-interacting multifunctional protein 3; Elongation factor p18; Multisynthase complex auxiliary component p18

Alternative UPACC:

O43324; C9JLK5; Q5THS2

Background:

Eukaryotic translation elongation factor 1 epsilon-1, also known by its alternative names such as Aminoacyl tRNA synthetase complex-interacting multifunctional protein 3, Elongation factor p18, and Multisynthase complex auxiliary component p18, plays a pivotal role in the cellular response to DNA damage. Its function as a positive modulator of ATM response underscores its critical involvement in maintaining genomic integrity.

Therapeutic significance:

Understanding the role of Eukaryotic translation elongation factor 1 epsilon-1 could open doors to potential therapeutic strategies. Its fundamental role in DNA damage response mechanisms positions it as a key target for developing novel treatments aimed at enhancing cellular resilience to genetic insults.